The NeurologyLive® movement disorders clinical focus page is a source for all the latest news regarding the clinical care of patients with Parkinson disease, essential tremor, Huntington disease, dystonia, ataxia, and more. This page features podcasts, videos, and news about FDA actions, study and clinical trial findings, clinical guideline updates, and interviews with experts in the clinical care of movement disorders.
August 29th 2025
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending August 29, 2025.
Mechanism of Stem Cell Therapy Bemdaneprocel for Parkinson Disease: Amit Rakhit, MD
October 9th 2024The chief medical officer and chief development officer at BlueRock Therapeutics discussed the promise behind bemdaneprocel and its unique mechanism of action relative to other Parkinson disease treatments. [WATCH TIME: 3 minutes]
Sage Therapeutics and Biogen Officially Announce Ending of SAGE-324 Program in Essential Tremor
October 3rd 2024The KINETIC 2 study did not show statistically significant improvement in essential tremor symptoms compared to placebo, leading to the termination of its development for this condition.
Continued Progress in Phase 1 Study of Antisense Oligonucleotide ION464 in MSA
October 2nd 2024ION464 is designed to inhibit the production of the alpha-synuclein protein, aiming to reduce the accumulation of this protein in the brain, which is believed to be a key factor driving neurodegeneration in MSA and Parkinson disease.
Potential Promise Behind ATH434 for Multiple System Atrophy: Daniel Claassen, MD, MS
October 2nd 2024The director of the Huntington’s Disease Clinic at Vanderbilt University Medical Center gave commentary on the unique development of ATH434, its ability to target iron accumulation, and how it may slow disease progression in multiple system atrophy. [WATCH TIME: 3 minutes]
Extended-Release Amantadine Shows Reduction in Dyskinesia Severity for Parkinson Disease
October 1st 2024Amantadine extended-release capsules, approved for levodopa-related dyskinesia and OFF episodes in Parkinson disease, offer high amantadine concentrations that peak in the time of first morning levodopa dose.
Positive 24-Month Data of Cell Therapy Bemdaneprocel in Parkinson Disease: Amit Rakhit, MD
October 1st 2024The chief medical officer and chief development officer at BlueRock Therapeutics provided perspective on newly presented data investigating a cell therapy for patients with Parkinson disease. [WATCH TIME: 4 minutes]
Mechanism Behind Ulixacaltamide to Treat Essential Tremor: Marcio Souza
October 1st 2024The president and chief executive officer at Praxis Precision Medicine provided clinical insight on the promising build of ulixacaltamide, an investigational, selective agent in development for essential tremor. [WATCH TIME: 3 minutes]
Randomized Controlled ELATE Study to Test OnabotulinumtoxinA in Upper Limb Essential Tremor
September 30th 2024ELATE, a multicenter, randomized, double-blind, placebo-controlled trial, aims to address the limitations of current oral therapies by exploring a targeted, localized treatment option.
Nocturnal and Morning Akinesia Still Prevalent After Nighttime Add-On Parkinson Medications
September 30th 2024In a post hoc analysis of the COSMOS study, 24-hour LCIG infusion led to a reduction in nocturnal and morning akinesia, though many patients continued to rely on nighttime add-on medications.
Potential of Device-Assisted Therapy for Advanced-Stage Parkinson Disease: David Devos, MD, PhD
September 29th 2024The neuropharmacologist at the University of Lille, in France, provided commentary on promising results from the phase 1/2 DIVE-I trial assessing the safety and efficacy of a device-assisted therapy in Parkinson disease. [WATCH TIME: 6 minutes]
Exploring the Treatment Possibilities and Functionality of High Intensity Focused Ultrasound
September 27th 2024Tim Miller, MD, director of functional neurosurgery at the Marcus Neuroscience Institute, Baptist Health, provided commentary on the use of HIFU as a non-invasive treatment for patients with essential tremor and specific types of Parkinson disease.
Expanding the Boundaries of Neurosurgical Care: Recent Advances Give Patients New Hope
September 27th 2024Innovative neurosurgical advances in imaging/mapping, robotic assistance, and extended reality enable surgeons to more precisely and effectively treat neurological conditions such as brain tumor, epilepsy, Parkinson Disease, and stroke, giving patients new hope and a chance for more successful outcomes.